12:00 AM
 | 
Feb 04, 2013
 |  BC Week In Review  |  Clinical News  |  Regulatory

Lucentis ranibizumab regulatory update

The Dutch Ministry of Health, Welfare and Sport said the country's Heath Care Insurance Board (CVZ) recommended the minister remove Lucentis ranibizumab for wet age-related macular degeneration (AMD) from the Netherlands' drug reimbursement list as of Jan. 1, 2015. A spokesperson for the minister told BioCentury that the CVZ...

Read the full 225 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$30 USD
More Info >